journal article·2025-01

Continuously producible aztreonam-loaded inhalable lipid nanoparticles for cystic fibrosis-associated Pseudomonas aeruginosa infections – Development and in-vitro characterization

Gautam Chauhan, Abdul A. Shaik, Shruti S. Sawant, Rimpy Diwan, Meghana Mokashi, Mimansa Goyal, Snehal K. Shukla, Nitesh K. Kunda, Vivek Gupta

Publisher page

Abstract

Cystic fibrosis (CF) is a genetic disorder affecting nearly 105,000 patients worldwide and is characterized by poor respiratory function due to accumulation of thick mucus in the lungs, which not just acts as a physical barrier, but also provides a breeding ground for bacterial infections. These infections can be controlled with the help of antibiotics which can be delivered directly into the lungs for amplifying the local anti-bacterial effect. More than 50 % of CF patients are associated with Pseudomonas aeruginosa infection in their lungs which requires antibiotics such as Aztreonam (AZT). In this study, we prepared inhalable AZT-loaded lipid nanoparticles using Hot-melt extrusion (HME) coupled with probe sonication to target Pseudomonas aeruginosa infection in the lungs. The optimized nanoparticles were tested for physicochemical properties, stability profile, in-vitro aerosolization, and antimicrobial activity against Pseudomonas aeruginosa. The optimized nanoparticles with a PEI concentration of 0.1 % demonstrated a uniform particle size of <50 nm, a spherical shape observed under a transmission electron microscope, and >70 % drug entrapment. Incorporating cationic polymer, PEI, resulted in sustained drug release from the lipid nanoparticles. The in-vitro aerosolization studies exhibited a mass median aerodynamic diameter (MMAD) of <4.3 μm, suggesting deposition of the nanoparticles in the respirable airway. The antimicrobial activity against Pseudomonas aeruginosa showed the minimum inhibitory concentration of the formulation is 2-fold lower than plain AZT. Stability profile showed the formulations are stable after exposure to accelerated conditions. In conclusion, hot-melt extrusion in combination with probe sonication can be used as a potential method for the continuous production of AZT-loaded lipid nanoparticles with enhanced anti-bacterial activity.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Inhalation and Respiratory Drug Delivery · Cystic Fibrosis Research Advances · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Warnock L, Gates A. Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis. Cochrane Database Syst. Rev. [Internet]. 2023;(4). [cited 2023 Oct 1], Available from: https://doi.org/10.1002/14651858.CD001401.pub4/full.10.1002/14651858.CD001401.pub4 ↗
2. Cystic fibrosis: pathophysiology of lung disease10.1055/s-0039-1694021 ↗
3. chapter-7-cystic-fibrosis.pdf [Internet]. [cited 2019 Oct 14]. Available from: https://www.thoracic.org/patients/patient-resources/breathing-in-america/resources/chapter-7-cystic-fibrosis.pdf.
4. Positive and negative impacts of elexacaftor/tezacaftor/ivacaftor: healthcare providers’ observations across US centers10.1002/ppul.26527 ↗
5. CFTR modulators for the treatment of cystic fibrosis
7. Biodegradable microparticles designed to efficiently reach and act on cystic fibrosis mucus barrier10.1016/j.msec.2018.10.064 ↗
8. Changing rates of chronic Pseudomonas aeruginosa infections in cystic fibrosis: a population-based cohort study10.1093/cid/ciy215 ↗
9. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis10.1016/j.ijpharm.2015.12.028 ↗
10. Cystic fibrosis: recent insights into inhaled antibiotic treatment and future perspectives
11. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis
12. Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis
13. A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis10.1016/j.jcf.2017.02.006 ↗
14. Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to penicillins10.1016/j.jaci.2014.10.011 ↗
15. Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell–mediated hypersensitivity to penicillins10.1016/j.jaci.2016.01.025 ↗
16. MedchemExpress.com [Internet]. [cited 2024 Feb 14]. Aztreonam (SQ-26,776) | Bacterial Inhibitor | MedChemExpress. Available from: https://www.medchemexpress.com/Aztreonam.html.
17. Aztreonam Injection: MedlinePlus Drug Information [Internet]. [cited 2023 Oct 3]. Available from: https://medlineplus.gov/druginfo/meds/a687010.html.
18. Dry powder inhalation for lung delivery in cystic fibrosis10.3390/pharmaceutics15051488 ↗
19. Inhaled aztreonam10.1038/nrd3170 ↗
20. Information NC for B · 2015
21. Taking Cayston | CAYSTON® (aztreonam for inhalation solution) [Internet]. [cited 2024 Jul 21]. Available from: https://www.cayston.com/taking-cayston.
22. Recent advances in materials for extended-release antibiotic delivery system | The Journal of Antibiotics [Internet]. [cited 2024 Jul 21]. Available from: https://www.nature.com/articles/ja201158.
23. ARIKAYCE® (amikacin liposome inhalation suspension) - Insmed [Internet]. [cited 2024 Jul 21]. Available from: https://insmed.com/science/our-pillars/arikayce/.
24. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa10.1016/j.jcf.2011.02.007 ↗
25. Montgomery
26. The influence of amino acids on aztreonam spray-dried powders for inhalation10.1016/j.ajps.2015.08.002 ↗
27. The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis10.1007/s40273-013-0122-x ↗
28. In vitro/in vivo evaluation of elastic nano-lipid carriers of Aztreonam for pneumonic lungs10.2174/2211738511666230223141759 ↗
29. Experimental design supported liposomal Aztreonam delivery: in vitro studies10.34172/apb.2021.074 ↗
30. Lipid-based pulmonary delivery system: a review and future considerations of formulation strategies and limitations10.1007/s13346-018-0550-4 ↗
31. Lipid nanoparticles as delivery vehicles for inhaled therapeutics10.3390/biomedicines10092179 ↗
32. Scalable production and in vitro efficacy of inhaled erlotinib nanoemulsion for enhanced efficacy in non-small cell lung cancer (NSCLC)10.3390/pharmaceutics15030996 ↗
33. Delivery strategies for sustained drug release in the lungs10.1016/j.addr.2014.05.017 ↗
34. Chauhan G, Shaik AA, Kulkarni NS, Gupta V. The preparation of lipid-based drug delivery system using melt extrusion. Drug Discov. Today [Internet]. 2020 Aug 21 [cited 2020 Oct 20]; Available from: http://www.sciencedirect.com/science/article/pii/S1359644620303305.
35. Nebulized oil-in-water nanoemulsion mists for pulmonary delivery: development, physico-chemical characterization and in vitro evaluation10.3109/03639045.2013.814065 ↗
36. Preparation and characterization of solid lipid nanoparticles loaded with epirubicin for pulmonary delivery
37. Nanostructured lipid carriers versus solid lipid nanoparticles for the potential treatment of pulmonary hypertension via nebulization
38. Nielsen CK, Kjems J, Mygind T, Snabe T, Meyer RL. Effects of tween 80 on growth and biofilm formation in laboratory media. Front. Microbiol. [Internet]. 2016 Nov 22 ;7. [cited 2019 Oct 10], Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118432/.10.3389/fmicb.2016.01878 ↗
39. Interactions of surfactants with the bacterial cell wall and inner membrane: revealing the link between aggregation and antimicrobial activity10.1021/acs.langmuir.2c02520 ↗
40. Surfactants as antimicrobials: a brief overview of microbial interfacial chemistry and surfactant antimicrobial activity10.1002/jsde.12293 ↗
41. Antibacterial activities of polyethylene glycol, tween 80 and sodium dodecyl sulphate coated silver nanoparticles in normal and multi-drug resistant bacteria10.1166/jnn.2012.6148 ↗
42. Recent technological advances in oral drug delivery – a review10.1016/S1461-5347(00)00247-9 ↗
43. Microemulsions are highly effective anti-biofilm agents10.1046/j.1472-765X.2003.01266.x ↗
44. Sequential treatment of biofilms with aztreonam and tobramycin is a novel strategy for combating Pseudomonas aeruginosa chronic respiratory infections10.1128/AAC.00196-16 ↗
45. Developments and Challenges: Adapting Continuous Manufacturing for Pharmaceuticals - AAPS News Magazine [Internet]. [cited 2019 Oct 3]. Available from: https://www.aapsnewsmagazine.org/articles/2019/apr19/cover-story-apr19.
46. Continuous production of fenofibrate solid lipid nanoparticles by hot-melt extrusion technology: a systematic study based on a quality by design approach10.1208/s12248-014-9674-8 ↗
47. A novel approach for the development of a nanostructured lipid carrier formulation by hot-melt extrusion technology10.1016/j.xphs.2016.12.015 ↗
48. A physically stabilized amorphous solid dispersion of nisoldipine obtained by hot melt extrusion10.1016/j.powtec.2016.06.032 ↗
49. Impact of change of matrix crystallinity and polymorphism on ovalbumin release from lipid-based implants10.1016/j.ejps.2018.02.019 ↗
50. New lipid-based formulation approaches/tools in hot-melt extrusion [internet]
51. Formulation development of itraconazole PEGylated nano-lipid carriers for pulmonary aspergillosis using hot-melt extrusion technology
52. Inhalable resveratrol-cyclodextrin complex loaded biodegradable nanoparticles for enhanced efficacy against non-small cell lung cancer10.1016/j.ijbiomac.2020.07.124 ↗
53. Inhaled indomethacin-loaded liposomes as potential therapeutics against non-small cell lung cancer (NSCLC)10.1007/s11095-022-03392-x ↗
54. Acidic microenvironment determines antibiotic susceptibility and biofilm formation of Pseudomonas aeruginosa
55. Simulated biological fluids with possible application in dissolution testing10.14227/DT180311P15 ↗
56. Bypassing P-glycoprotein mediated efflux of afatinib by cyclodextrin complexation – evaluation of intestinal absorption and anti-cancer activity10.1016/j.molliq.2020.114866 ↗
57. Eugenol-chitosan nanoemulsions by ultrasound-mediated emulsification: formulation, characterization and antimicrobial activity10.1016/j.carbpol.2018.03.101 ↗
58. Poly vinyl pyrrolidone (PVP) based inhaled delivery carriers for olaparib for non-small cell lung cancer (NSCLC) treatment
59. Wang Q, Zhang H, Han Y, Cui Y, Han X. Study on the relationships between the oil HLB value and emulsion stabilization. RSC Adv. 13(35):24692–8.10.1039/D3RA04592G ↗
60. Gattefossé [Internet]. [cited 2024 Jul 21]. Labrafac™ Lipophile WL 1349 · Gattefossé. Available from: https://www.gattefosse.com/pharmaceuticals/product-finder/labrafac-lipophile-wl-1349.
61. Self-nanoemulsifying drug delivery system (SNEDDS) mediated improved oral bioavailability of thymoquinone: optimization, characterization, pharmacokinetic, and hepatotoxicity studies - PMC [Internet]. [cited 2024 Jul 21]. Available from: https://www-ncbi-nlm-nih-gov.jerome.stjohns.edu/pmc/articles/PMC9726673/.
62. Labrafil® M 1944 CS · Gattefossé [Internet]. [cited 2024 Jul 21]. Available from: https://www.gattefosse.com/pharmaceuticals/product-finder/labrafil-m-1944-cs.
63. Gattefossé [Internet]. [cited 2024 Jul 21]. Labrafil® M 2125 CS · Gattefossé. Available from: https://www.gattefosse.com/pharmaceuticals/product-finder/labrafil-m-2125-cs.
64. Development of solid self-emulsifying formulation for improving the oral bioavailability of Erlotinib10.1208/s12249-015-0370-5 ↗
65. Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis10.1007/s11095-008-9641-0 ↗
66. Preparation and bioavailability assessment of SMEDDS containing valsartan10.1208/s12249-010-9385-0 ↗
67. Assessing the stability of tween 80-based O/W emulsions with cyclic voltammetry and electrical impedance spectroscopy10.1016/j.colsurfa.2016.09.074 ↗
68. The effects of glycols on molecular mobility, structure, and permeability in stratum corneum10.1016/j.jconrel.2022.02.007 ↗
69. CCRD based development of bromocriptine and glutathione nanoemulsion tailored ultrasonically for the combined anti-parkinson effect10.1016/j.chemphyslip.2020.105035 ↗
70. The importance of the cosolvent propylene glycol on the antimicrobial preservative efficacy of a pharmaceutical formulation by DOE-ruggedness testing10.1080/10837450600767342 ↗
71. Preparation and evaluation of sterically stabilized liposomes: colloidal stability, serum stability, macrophage uptake, and toxicity10.1002/jps.2600790803 ↗
72. Intranasal delivery of Naloxone-loaded solid lipid nanoparticles as a promising simple and non-invasive approach for the management of opioid overdose - ScienceDirect [Internet]. [cited 2024 Feb 10]. Available from: https://www-sciencedirect-com.jerome.stjohns.edu/science/article/pii/S0378517321002325.
73. Influence of PEI as a core modifying agent on PLGA microspheres of PGE₁, a pulmonary selective vasodilator10.1016/j.ijpharm.2011.04.017 ↗
74. Non-viral approach toward gene therapy of cystic fibrosis lung disease10.2174/1566523023347832 ↗
75. Emulsion formation and stabilization by biomolecules: the leading role of cellulose10.3390/polym11101570 ↗
76. Salawi A. Self-emulsifying drug delivery systems: a novel approach to deliver drugs. Drug Deliv. 29(1):1811–23.10.1080/10717544.2022.2083724 ↗
77. Controlling the morphology of poly(ethyleneimine)/gold nanoassemblies through the variation of pH and electrolyte additives - ScienceDirect [Internet]. [cited 2024 Jul 21]. Available from: https://www.sciencedirect.com/science/article/pii/S0167732220342215.
78. Role of four different kinds of Polyethylenimines (PEIs) in preparation of polymeric lipid nanoparticles and their anticancer activity study10.7150/jca.13855 ↗
79. Development of pharmaceutically scalable inhaled anti-cancer nanotherapy – repurposing amodiaquine for non-small cell lung cancer (NSCLC)
80. The forces at work in colloidal self-assembly: a review on fundamental interactions between colloidal particles10.1002/apj.144 ↗
81. Chitosan/bovine serum albumin layer-by-layer assembled particles for non-invasive inhaled drug delivery to the lungs10.1016/j.ijbiomac.2024.132526 ↗
82. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics | Experimental & Molecular Medicine [Internet]. [cited 2024 Jul 21]. Available from: https://www.nature.com/articles/s12276-023-01086-x.
83. Impact of lipid nanoparticle size on mRNA vaccine immunogenicity10.1016/j.jconrel.2021.05.021 ↗
84. Competition between hydrogen bonding and electrostatic repulsion in pH-switchable emulsions10.1016/j.molliq.2023.123095 ↗
85. 78110-38-0 CAS MSDS (Aztreonam) Melting Point Boiling Point Density CAS Chemical Properties [Internet]. [cited 2020 Oct 12]. Available from: https://www.chemicalbook.com/ChemicalProductProperty_US_CB0386184.aspx.
86. Florey · 1972
87. Development of sustained release lipid-based matrix microparticles for vaginal delivery using twin-screw hot melt extrusion [internet]
88. Surface-modified inhaled microparticle-encapsulated celastrol for enhanced efficacy in malignant pleural mesothelioma10.3390/ijms24065204 ↗
89. Development and characterization of inhaled nintedanib-loaded PLGA nanoparticles using scalable high-pressure homogenization technique
90. Effect of polyethyleneimine on the properties of concentrated suspensions of titanium dioxide microbeads10.1016/S1672-2515(07)60054-2 ↗
91. Effect of block and graft copolymers on the stability of colloidal silica10.1006/jcis.1998.5946 ↗
92. Afatinib-loaded inhalable PLGA nanoparticles for localizedtherapy of non-small cell lung cancer (NSCLC)—development and in-vitroefficacy10.1007/s13346-020-00802-8 ↗
93. Cyclodextrin complexation for enhanced stability and non-invasive pulmonary delivery of resveratrol—applications in non-small cell lung cancer treatment10.1208/s12249-020-01724-x ↗
94. Poly(lactide-co-glycolide)/cyclodextrin (polyethyleneimine) microspheres for controlled delivery of dexamethasone10.1016/j.reactfunctpolym.2016.08.008 ↗
95. Kinetic modeling on drug release from controlled drug delivery systems
96. Polyethylenimine-based nanocarriers in co-delivery of drug and gene: a developing horizon10.1080/20022727.2018.1488497 ↗
97. One-step synthesis of polyethylenimine-coated magnetic nanoparticles and its demulsification performance in surfactant-stabilized oil-in-water emulsion10.1080/01932691.2018.1467773 ↗
98. Gardenhire DS, Nozart L, Hinski ST. Aerosol Delivery Devices for Respiratory Therapists.
99. Electrostatic charge characteristics of jet nebulized aerosols10.1089/jamp.2009.0795 ↗
100. Development of inhalable quinacrine loaded bovine serum albumin modified cationic nanoparticles: repurposing quinacrine for lung cancer therapeutics10.1016/j.ijpharm.2019.118995 ↗